In addition, studies have also shown that the overall response rate of melanoma patients treated with a combination of the oncolytic virus Imlygic (T-VEC) and the checkpoint inhibitor CTLA-4 antibody, has doubled compared with a single treatment with Yervoy (Ipilimumab) CTLA-4 antibody (42). Here, CTLA4 is linked to melanoma.